Introduction
Methods
Study design
Patient identification and data collection
Clinical suspicion
Patient outcomes
Statistical analysis
Results
Study population and missing data
Patient characteristics, symptoms and signs
In first DD (n = 138) | Not in first DD (n = 62) |
P
| |||
---|---|---|---|---|---|
Age | 64 | (54–73) | 65 | (56–72) | 0.74 |
Female sex | 47 | (34.0) | 31 | (50.1) | 0.046 |
BMI | 26 | (24–29) | 26 | (24–29) | 0.90 |
Current smoking | 56 | (40.9) | 23 | (36.9) | 0.67 |
History of:
| |||||
Hypertension | 78 | (56.3) | 41 | (66.5) | 0.22 |
COPD | 26 | (18.8) | 13 | (21.6) | 0.66 |
Diabetes mellitus | 9 | (6.5) | 5 | (7.2) | 0.84 |
Extracardiac atherosclerosis | 25 | (18.4) | 19 | (30.0) | 0.09 |
Connective tissue disease | 17 | (12.3) | 2 | (3.0) | 0.10 |
Myocardial infarction | 14 | (10.2) | 7 | (11.0) | 0.88 |
Neurological dysfunction | 17 | (12.6) | 12 | (19.2) | 0.24 |
Previous aortic dissection | 7 | (5.2%) | 1 | (1.4%) | 0.99 |
Cardiac surgery | 13 | (9.6) | 4 | (6.8) | 0.56 |
Bicuspid aortic valve | 10 | (12.3) | 2 | (3.4) | 0.36 |
In first DD (n = 138) | Not in first DD (n = 62) |
P
| |||
---|---|---|---|---|---|
Stanford type A AD | 108,108 | (78.3) | 44 | (70.9) | 0.210.28 |
Intramural haematoma | 6 | (4.3) | 3 | (4.8) | 0.85 |
Symptoms
| |||||
Chest pain | 89 | (64.7) | 38 | (61.3) | 0.68 |
Back pain | 77 | (56.1) | 19 | (31.0) | 0.004 |
Abdominal pain | 33 | (23.7) | 15 | (24.0) | 0.98 |
No pain reported | 14 | (10.2) | 11 | (18.2) | 0.15 |
Migration of pain | 28 | (20.0) | 6 | (9.5) | 0.16 |
Sudden onset | 110 | (79.4) | 42 | (67.9) | 0.10 |
Focal neurological deficit | 22 | (15.8) | 6 | (9.9) | 0.23 |
TLOC | 27 | (19.5) | 7 | (10.7) | 0.18 |
Coma | 17 | (12.1) | 7 | (10.7) | 0.77 |
Signs
| |||||
Any pulse deficit | 29 | (20.7) | 6 | (9.9) | 0.13 |
Heart rate | 73 | (62–90) | 78 | (65–90) | 0.19 |
Systolic BP (mm Hg) | 120 | (95–160) | 120 | (105–170) | 0.53 |
Diastolic BP (mm Hg) | 67 | (50–85) | 70 | (60–90) | 0.35 |
Haemoglobin (mmol/l) | 7.8 | (6.6–8.7) | 8.0 | (7.5–8.9) | 0.18 |
Creatinine (μmol/l) | 104 | (90–128) | 102 | (85–127) | 0.92 |
Diagnostic tests
In first DD (n = 138) | Not in first DD (n = 62) |
P
| |||
---|---|---|---|---|---|
First imaging test
| |||||
TTE | 43 | (36.1) | 28 | (50.9) | 0.002* |
CT | 53 | (44.5) | 16 | (29.1) | – |
TEE | 18 | (15.1) | 3 | (5.5) | – |
MRI | 3 | (2.5) | 0 | (0) | – |
CAG | 1 | (0.8) | 5 | (9.1) | – |
All imaging tests
| |||||
TTE | 62 | (52.1) | 39 | (70.9) | 0.02 |
CT | 92 | (77.3) | 37 | (67.3) | 0.16 |
TEE | 54 | (45.4) | 23 | (42.6) | 0.73 |
MRI | 6 | (5.0) | 4 | (7.3) | 0.56 |
CAG | 3 | (2.5) | 10 | (18.2) | <0.001 |
Clinical suspicion
RR | (95% CI) |
P
| |
---|---|---|---|
Female sex | 0.66 | 0.44–0.99 | 0.04 |
Age | 0.99 | 0.98–1.01 | 0.55 |
Extracardiac atherosclerosis | 0.64 | 0.43–0.96 | 0.03 |
Connective tissue disease | 3.17 | 0.49–20.7 | 0.23 |
Absence of back pain | 0.51 | 0.30–0.84 | 0.008 |
Migratory pain | 1.37 | 0.42–4.39 | 0.60 |